← Leaderboards
Joseph Dougherty
Univ Of Med/Dent Nj-R W Johnson Med Sch
$6,079,984
Attributed
$6,079,984
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $538.8K · FY2006–16$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,079,984 · 7
By mechanism
R01$4,558,376 · 3
R42$558,030 · 1
R21$434,529 · 1
R33$402,489 · 1
R41$126,560 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Tariq M Rana$51,311,096
- David J Foran$10,512,858
- Nicola C Partridge$12,944,198
- Danny F Reinberg$17,590,334
- Terri Goss Kinzy$7,949,810
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsResearch StudyDesignSmall MoleculeCellsRegulationIn VivoBaseGene Expression RegulationGene ExpressionProteinsClone CellsProductionMonitorAttentionGenesPublic Health RelevanceApoptosisApomorphineAnimalsCorpus Striatum StructureClinical EfficacyDisease ModelFlexibility
Grant awards (20)
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity$402,489
R33 · FY2016 · AI · contact PI
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity$119,250
R21 · FY2015 · AI · contact PI
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity$315,279
R21 · FY2014 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$189,503
R01 · FY2013 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$173,378
R01 · FY2013 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$371,939
R01 · FY2012 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$378,941
R01 · FY2011 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$382,897
R01 · FY2010 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$84,648
R01 · FY2010 · AI · contact PI
Gene regulation using novel drugs modulating premature translational termination$382,689
R01 · FY2009 · AI · contact PI
High Throughput Screening to Identify Antagonists of HIV-1 Latency$503,993
R01 · FY2008 · AI · contact PI
High Throughput Screening to Identify Antagonists of HIV-1 Latency$503,638
R01 · FY2007 · AI · contact PI
High Throughput Screening to Identify Antagonists of HIV-1 Latency$538,765
R01 · FY2006 · AI · contact PI
A virus/cell based assay for discovery of anti-HIV drugs$279,015
R42 · FY2004 · AI
A virus/cell based assay for discovery of anti-HIV drugs$279,015
R42 · FY2003 · AI
DETERMINATION OF RETROVIRUS MUTATION RATES$273,724
R01 · FY2003 · CA
DETERMINATION OF RETROVIRUS MUTATION RATES$265,751
R01 · FY2002 · CA
A virus/cell based assay for discovery of anti-HIV drugs$126,560
R41 · FY2002 · AI
DETERMINATION OF RETROVIRUS MUTATION RATES$258,014
R01 · FY2001 · CA
DETERMINATION OF RETROVIRUS MUTATION RATES$250,496
R01 · FY2000 · CA